1. Terry TL. Extreme prematurity and
fibroblastic overgrowth of persistent
vascular sheath behind each crystalline
lens. Am J Ophthalmol 1942;25:203-204.
2. Quiram PA, Capone A Jr. Current
understanding and management of
retinopathy of prematurity. Curr Opin
Ophthalmol. 2007;18:228-34.
3. Good WV, Hardy RJ, DObson V, et al. Early
Treatment for Retinopathy of Prematurity
Cooperative Group. The incidence and
course of retinopathy of prematurity:
findings from the Early Treatment for
Retinopathy of Prematurity Study.
Pediatrics 2005;116:15-23.
4. McLoone E, O’Keefe M, Lanigan B. Effect
of diode laser retinal ablative therapy
for threshold retinopathy of prematurity
on the visual field: Results of Goldmann
Perimetry at a mean age of 11 years. J
Pediatr Ophthalmol Strabismus 2007;
144:170–173.
5. Quinn G, Dobson V, Davitt B, et al.
Progression of myopia and high myopia
in the early treatment for retinopathy of
prematurity study: findings to 3 years of
age. Ophthalmology 2008; 115:1058–
1064.
6. Chen J, Smith L. Retinopathy of
Prematurity. Angiogenesis 2007; 10:133–
140.
7. Mintz-Hittner HA, Best LM. Antivascular
endothelial growth factor for retinopathy
of prematurity. Curr Opin Pediatr.
2009;21:182-7.
8. Charles BJ, Ganthier R, Appiah AA.
Incidence and characteristics of
retinopathy of prematurity in a low-income
inner-city population. Ophthalmology
1991;98:14–17.
9. Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Prognostic factors
in the natural course of retinopathy
of prematurity (Palmer EA, Schaffer
DB, Plotsky DF: The Cryotherapy for
Retinopathy of Prematurity Cooperative
Group). Ophthalmology 1993;100:230–
273.
10. Phelps DL, Brown DR, Tung B, et al. 28-
Day survival rates of 6676 neonates with
birth weights of 1250 grams or less.
Pediatrics 1991;87:7–17
11. Ober RR, Palmer EA, Drack AV, Wright
KW. Retinopathy of Prematurity. Wright
KW,Spiegel PH, Thompson LS, eds.
Handbook of Pediatric Retinal Disease.
New York: Springer, 2006,pp.284-349.
12. Palmer EA, Flynn JT, Hardy RJ, Phelps
DL, Phillips CL, Schaffer DB, Tung B.
Incidence and early course of retinopathy
of prematurity. Ophthalmology 1991;
98:1628-40
13. Phelps DL. Retinopathy of Prematurity.In:
Martin RJ, Fanaroff AA, Walsh MC (eds).
Fanaroff and Martin’s Neonatal-Perinatal
Medicine Diseases of the Fetus and
Infant, 8th ed, Philadelphia: Mosby, 2006,
pp.1747-52.
14. Shohat M, Reisner SH, Krikler R, et al.
Retinopathy of prematurity: Incidence and
risk factors. Pediatrics 1983;72:159–163.
15. Gunn TR, Easdown J, Outerbridge EW,
Aranda JV. Risk factors in retrolental
fibroplasia. Pediatrics 1980;65:1096–
1100
16. Hammer ME, Mullen PW, Ferguson JG, Pai
S, Cosby C, Jackson KL. Logistic analysis
ofrisk factors in acute retinopathy of
prematurity. Am J Ophthalmol 1986;102:
1–6
17. Darlow BA, Horwood L J, Clement RS.
Retinopathy of prematurity:risk factors
in a prospective population-based study.
Paediatr Perinatal Epidemiol 1992;6:62–
80.
18. Charles BJ, Ganthier R, Appiah AA.
Incidence and characteristics of
retinopathy of prematurity in a low-income
inner-city population. Ophthalmology
1991;98:14–17
19. Seiberth V, Linderkamp O. Risk factors in
retinopathy of prematurity:a multivariate
statistical analysis. Ophthalmologica
2000; 214:131–135
20. Mutlu FM, Altinsoy HI, Mumcuoglu T,
Kerimoglu H, Kiliç S, Kul M, Sarici SU,
Alpay F. Screening for retinopathy of
prematurity in a tertiary care newborn
unit in Turkey: frequency, outcomes, and
risk factor analysis.J Pediatr Ophthalmol
Strabismus. 2008;45(5):291-8.
21. Glass P, Avery GB, Kolinjavadi N, et
al. Effect of bright light in the hospital
nursery on the incidence of retinopathy
of prematurity. N Engl J Med 1985;313:
401–404
22. Reynolds JD, Hardy RJ, Kennedy KA, et
al. Lack of efficacy of lightreduction in
preventing retinopathy of prematurity.
Light-ROP Cooperative Group. N Engl J
Med 1998;338:1572–1576
23. ICROP Committee: International
classification of retinopathy of prematurity.
Arch Ophthalmol 1984;102:1130-1134.
24. ICROP Commiittee for classification of
late stages of ROP: An international
classification of retinopathy of prematurity
II. The classification of retinal detachment.
Arch Ophthalmol 1987; 105:906-912.
25. An International Committee for
the Classification of Retinopathy
of Prematurity. The international
classification of retinopathy of prematurity
– revisited. Arch Ophthalmol 2005; 123:
991-999.
26. Repka MX, Palmer EA, Tung B. Involution
of retinopathy of prematurity. Cryotherapy
for Retinopathy of Prematurity Cooperative
Group. Arch Ophthalmol. 2000;118:645-
9.
27. Palmer EA, Flynn JT, Hardy RJ, Phelps
DL, Phillips CL, Schaffer DB, Tung B.
Incidence and early course of retinopathy
of prematurity. The Cryotherapy for
Retinopathy of Prematurity Cooperative
Group. Ophthalmology. 1991;98:1628-
40.
28. Cryotherapy for Retinopathy of Prematurity
Cooperative Group: Natural history of
retinopathy of prematurity (ROP): The
natural ocular outcome of premature birth
and retinopathy: Status ay one year. Arch
Ophthalmol 1994;112:903-912.
29. Birch EE, O’Connor AR. Preterm birth and
visual development. Semin Neonatol.
2001;6:487-97.
30. Retinopathy of prematurity: guidelines for
screening and treatment. The report of a
Joint Working Party of The Royal College
of Ophthalmologists and the British
Association of Perinatal Medicine. Early
Hum Dev. 1996;46:239-58.
31. Haines L, Fielder AR, Scrivener R,
Wilkinson AR; Royal College of Paediatrics
and Child Health, the Royal College of
Ophthalmologists and British Association
of Perinatal Medicine. Retinopathy of
prematurity in the UK I: the organisation
of services for screening and treatment.
Eye. 2002;16:33-8.
32. Fierson W, Flynn J, Good W, et al.
Screening examination of premature
infants for retinopathy of prematurity.
Pediatrics 2006;117:572-576.
33. Gilbert C, Fielder A, Gordillo L, Quinn G,
Semiglia R, Visintin P, Zin A; International
NO-ROP Group. Characteristics of infants
with severe retinopathy of prematurity
in countries with low, moderate, and
high levels of development: implications
for screening programs. Pediatrics.
2005;115:518-25.
34. Schwartz SD, Harrison SA, Ferrone PJ,
Trese MT. Telemedical evaluation and
management of retinopathy of prematurity
using a fiberoptic digital fundus camera.
Ophthalmology. 2000;107:25-8.
35. Roth DB, Morales D, Feuer WJ, Hess
D, Johnson RA, Flynn JT. Screening for
retinopathy of prematurity employing the
retcam 120: sensitivity and specificity.
Arch Ophthalmol. 2001;119:268-72.
36. Yen KG, Hess D, Burke B, Johnson RA,
Feuer WJ, Flynn JT. Telephotoscreening
to detect retinopathy of prematurity:
preliminary study of the optimum time to
employ digital fundus camera imaging to
detect ROP. J AAPOS. 2002 ;6:64-70.
37. Trese MT. What is the real gold satndart
for ROP screening? Retina. 2008;3:1-2
38. Johnson L, Bowen FW Jr, Abbasi S,
Herrmann N, Weston M, Sacks L, Porat
R, Stahl G, Peckham G, DelivoriaPapadopoulos M, et al. Relationship of
prolonged pharmacologic serum levels
of vitamin E to incidence of sepsis
and necrotizing enterocolitis in infants
with birth weight 1,500 grams or less.
Pediatrics. 1985;75:619-38.
39. Rosenbaum AL, Phelps DL, Isenberg SJ,
Leake RD, Dorey F. Retinal hemorrhage in
retinopathy of prematurity associated with
tocopherol treatment. Ophthalmology.
1985;92:1012-4.
40. Ashton N, Ward B, Serpell G. Effect of
oxygen on developing retinal vessels with
particular reference to the problem of
retrolental fibroplasia. Br J Ophthalmol.
1954;38:397-432.
41. Phelps DL. Reduced severity of oxygeninduced retinopathy in kittens recovered
in 28% oxygen. Pediatr Res. 1988;24:
106-9.
42. Supplemental Therapeutic Oxygen for
Prethreshold Retinopathy Of Prematurity
(STOP-ROP), a randomized, controlled
trial. I: primary outcomes. Pediatrics.
2000;105:295-310.
43. Multicenter trial of cryotherapy for
retinopathy of prematurity. Preliminary
results. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Arch
Ophthalmol. 1988 ;106:471-9.
44. Early Treatment For Retinopathy Of
Prematurity Cooperative Group.Revised
indications for the treatment of
retinopathy of prematurity: results of
the early treatment for retinopathy
of prematurity randomized trial. Arch
Ophthalmol. 2003;121:1684-94.
45. Hardy RJ, Palmer EA, Schaffer DB, Phelps
DL, Davis BR, Cooper CJ. Outcome-based
management of retinopathy of prematurity.
Multicenter Trial of Cryotherapy for
Retinopathy of prematurity Cooperative
Group. J AAPOS. 1997;1:46-54.
46. Hardy RJ, Palmer EA, Dobson V, Summers
CG, Phelps DL, Quinn GE, Good WV,
Tung B; Cryotherapy for Retinopathy
of Prematurity Cooperative Group.Risk
analysis of prethreshold retinopathy of
prematurity. Arch Ophthalmol. 2003;121:
1697-701.
47. Christiansen SP, Bradford JD.Cataract
in infants treated with argon laser
photocoagulation for threshold retinopathy
of prematurity. Am J Ophthalmol.
1995;119:175-80.
48. Capone A Jr, Trese MT. Lens-sparing
vitreous surgery for tractional stage
4A retinopathy of prematurity retinal
detachments. Ophthalmology. 2001;108:
2068-70.
49. Seaber JH, Machemer R, Eliott D, Buckley
EG, deJuan E, Martin DF. Long-term visual
results of children after initially successful
vitrectomy for stage V retinopathy of
prematurity. Ophthalmology. 1995;102:
199-204.
50. Quinn GE, Dobson V, Barr CC, Davis
BR, Palmer EA, Robertson J, Summers
CG, Trese MT, Tung B. Visual acuity of
eyes after vitrectomy for retinopathy
of prematurity: follow-up at 5 1/2
years. The Cryotherapy for Retinopathy
of Prematurity Cooperative Group.
Ophthalmology. 1996;103:595-600.
51. Quinn GE, Dobson V, Barr CC, Davis BR,
Flynn JT, Palmer EA, Robertson J, Trese MT.
Visual acuity in infants after vitrectomy
for severe retinopathy of prematurity.
Ophthalmology. 1991;98:5-13.
52. Lashkari K, Hirose T, Yazdany J, McMeel
JW, Kazlauskas A, Rahimi N. Vascular
endothelial growth factor and hepatocyte
growth factor levels are differentially
elevated in patients with advanced
retinopathy of prematurity. Am J Pathol
2000;156:1337–1344.
53. Sonmez K, Drenser KA, CaponeAJr, Trese
MT. Vitreous levels of stromal cell-derived
factor 1 and vascular endothelial growth
factor in patients with retinopathy of
prematurity. Ophthalmology 2008;115:
1065–1070.
54. Quiroz-Mercado H, MartinezCastellanosM,Hernandez-Rojas M,
Salazar-Teran N, Chan P. Antiangiogenic
therapy with intravitreal bevacizumab
for retinopathy of prematurity. Retina
2008;28:19-25.
55. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal
injection of bevacizumab (avastin) for
treatment of stage 3 retinopathy of
prematurity in zone I or posterior zone II.
Retina 2008;28:831–838.
56. Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Contrast
sensitivity at age 10 years in children who
had threshold retinopathy of prematurity.
Arch Ophthalmol. 2001;119:1129-33.
57. Sebris SL, Dobson V, Hartmann EE.
Assessment and prediction of visual acuity
in 3- to 4-year-old children born prior to
term. Hum Neurobiol. 1984;3:87-92.
58. Cats BP, Tan KE. Prematures with
and without regressed retinopathy of
prematurity: comparison of long-term (6-
10 years) ophthalmological morbidity. J
Pediatr Ophthalmol Strabismus. 1989;26:
271-5.
59. Colvin M, McGuire W, Fowlie PW.
Neurodevelopmental outcomes after
preterm birth. BMJ. 2004;329:1390-3.
Thank you for copying data from http://www.arastirmax.com
